111 related articles for article (PubMed ID: 16859756)
1. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.
Dong XN; Chen YH
Immunol Lett; 2006 Aug; 106(2):180-6. PubMed ID: 16859756
[TBL] [Abstract][Full Text] [Related]
2. The neutralizing epitope ELDKWA on HIV-1 gp41: genetic variability and antigenicity.
Dong XN; Wu Y; Chen YH
Immunol Lett; 2005 Oct; 101(1):81-6. PubMed ID: 15951025
[TBL] [Abstract][Full Text] [Related]
3. Genetic variability of principal neutralizing determinants on HIV-1 gp41 and its correlation with subtypes.
Dong XN; Ying J; Wu Y; Chen YH
Immunol Lett; 2005 Oct; 101(1):104-7. PubMed ID: 15961163
[TBL] [Abstract][Full Text] [Related]
4. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
Li J; Chen X; Jiang S; Chen YH
Biochem Biophys Res Commun; 2008 Nov; 376(1):60-4. PubMed ID: 18762167
[TBL] [Abstract][Full Text] [Related]
5. Binding antibody to neutralizing epitope gp41 in HIV-1 subtype CRF 01_AE infection related to stage of disease.
Srisurapanon S; Louisirirotchanakul S; Sumransurp K; Ratanasrithong M; Chuenchitra T; Jintakatkorn S; Wasi C
Southeast Asian J Trop Med Public Health; 2005 Jan; 36(1):221-7. PubMed ID: 15906673
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a trimeric MPER containing HIV-1 gp41 antigen.
Hinz A; Schoehn G; Quendler H; Hulsik DL; Stiegler G; Katinger H; Seaman MS; Montefiori D; Weissenhorn W
Virology; 2009 Aug; 390(2):221-7. PubMed ID: 19539967
[TBL] [Abstract][Full Text] [Related]
7. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
[TBL] [Abstract][Full Text] [Related]
8. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
Menendez A; Chow KC; Pan OC; Scott JK
J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
[TBL] [Abstract][Full Text] [Related]
11. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
Dong XN; Xiao Y; Chen YH
Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5.
Kusov YY; Zamjatina NA; Poleschuk VF; Michailov MI; Morace G; Eberle J; Gauss-Müller V
Antiviral Res; 2007 Feb; 73(2):101-11. PubMed ID: 17014915
[TBL] [Abstract][Full Text] [Related]
13. A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.
Huang J; Dong X; Liu Z; Qin L; Chen YH
Immunol Lett; 2002 Dec; 84(3):205-9. PubMed ID: 12413738
[TBL] [Abstract][Full Text] [Related]
14. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
[TBL] [Abstract][Full Text] [Related]
15. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
[TBL] [Abstract][Full Text] [Related]
17. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
Liu Z; Chen YH
J Immunol Methods; 2004 Feb; 285(1):93-7. PubMed ID: 14871538
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
Virology; 2017 May; 505():113-126. PubMed ID: 28237764
[TBL] [Abstract][Full Text] [Related]
19. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
20. Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen.
Jain S; Patrick AJ; Rosenthal KL
Vaccine; 2010 Oct; 28(43):7070-80. PubMed ID: 20723627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
